117 related articles for article (PubMed ID: 23617261)
1. Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use.
Lee SE; Bairstow SF; Werling JO; Chaubal MV; Lin L; Murphy MA; DiOrio JP; Gass J; Rabinow B; Wang X; Zhang Y; Yang Z; Hoffman RM
Pharm Dev Technol; 2014 Jun; 19(4):438-53. PubMed ID: 23617261
[TBL] [Abstract][Full Text] [Related]
2. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy.
Talekar M; Ganta S; Amiji M; Jamieson S; Kendall J; Denny WA; Garg S
Int J Pharm; 2013 Jun; 450(1-2):278-89. PubMed ID: 23632263
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of paclitaxel nanosuspension using novel emulsification method by combining high speed homogenizer and high pressure homogenization.
Li Y; Zhao X; Zu Y; Zhang Y
Int J Pharm; 2015 Jul; 490(1-2):324-33. PubMed ID: 26027492
[TBL] [Abstract][Full Text] [Related]
4. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
[TBL] [Abstract][Full Text] [Related]
5. Globular protein-coated Paclitaxel nanosuspensions: interaction mechanism, direct cytosolic delivery, and significant improvement in pharmacokinetics.
Li Y; Wu Z; He W; Qin C; Yao J; Zhou J; Yin L
Mol Pharm; 2015 May; 12(5):1485-500. PubMed ID: 25799282
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo.
Tang XJ; Fu YH; Meng QH; Li LM; Ying XY; Han M; He QJ; Yang B; Zeng S; Hu YZ; Sheng XX; Gao JQ
Int J Pharm; 2013 Nov; 456(1):243-50. PubMed ID: 23928148
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
[TBL] [Abstract][Full Text] [Related]
8. Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor.
Danhier F; Ucakar B; Vanderhaegen ML; Brewster ME; Arien T; Préat V
Eur J Pharm Biopharm; 2014 Sep; 88(1):252-60. PubMed ID: 24859391
[TBL] [Abstract][Full Text] [Related]
9. Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation.
Wang Y; Song J; Chow SF; Chow AH; Zheng Y
Int J Pharm; 2015 Oct; 494(1):479-89. PubMed ID: 26302857
[TBL] [Abstract][Full Text] [Related]
10. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity.
Wang Y; Ma Y; Zheng Y; Song J; Yang X; Bi C; Zhang D; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):728-35. PubMed ID: 23089583
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
15. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of intravenously injectable curcumin nanosuspension.
Gao Y; Li Z; Sun M; Guo C; Yu A; Xi Y; Cui J; Lou H; Zhai G
Drug Deliv; 2011 Feb; 18(2):131-42. PubMed ID: 20939679
[TBL] [Abstract][Full Text] [Related]
17. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
18. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
Devalapally H; Shenoy D; Little S; Langer R; Amiji M
Cancer Chemother Pharmacol; 2007 Mar; 59(4):477-84. PubMed ID: 16862429
[TBL] [Abstract][Full Text] [Related]
19. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery.
Wang Y; Li X; Wang L; Xu Y; Cheng X; Wei P
Int J Nanomedicine; 2011; 6():1497-507. PubMed ID: 21796250
[TBL] [Abstract][Full Text] [Related]
20. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
Pulkkinen M; Pikkarainen J; Wirth T; Tarvainen T; Haapa-aho V; Korhonen H; Seppälä J; Järvinen K
Eur J Pharm Biopharm; 2008 Sep; 70(1):66-74. PubMed ID: 18555675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
